Page 1904 - Hematology_ Basic Principles and Practice ( PDFDrive )

1684.e2 Part X Transplantation

42. Ferrara JL, Levine JE, Reddy P, et al: Graft-versus-host disease. Lancet disease: a randomized phase 2 trial from the Blood and Marrow Trans-
373(9674):1550–1561, 2009. plant Clinical Trials Network. Blood 114(3):511–517, 2009.
43. MacMillan ML, Weisdorf DJ, Brunstein CG, et al: Acute graft-versus- 47. Bolanos-Meade J, Logan BR, Alousi AM, et al: Phase 3 clinical trial
host disease after unrelated donor umbilical cord blood transplantation: of steroids/mycophenolate mofetil vs steroids/placebo as therapy for
analysis of risk factors. Blood 113(11):2410–2415, 2009. acute GVHD: BMT CTN 0802. Blood 124(22):3221–3227, 2014;
44. Devine SM, Carter S, Soiffer RJ, et al: Low risk of chronic graft-versus- quiz 335.
host disease and relapse associated with T cell-depleted peripheral blood 48. Filipovich AH, Weisdorf D, Pavletic S, et al: National Institutes
stem cell transplantation for acute myelogenous leukemia in first remis- of Health consensus development project on criteria for clinical
sion: results of the blood and marrow transplant clinical trials network trials in chronic graft-versus-host disease: I. Diagnosis and staging
protocol 0303. Biol Blood Marrow Transplant 17(9):1343–1351, 2011. working group report. Biol Blood Marrow Transplant 11(12):945–956,
45. Weisdorf D: GVHD the nuts and bolts. Hematology Am Soc Hematol 2005.
Educ Program 62–67, 2007. 49. Holtan SG, DeFor TE, Lazaryan A, et al: Composite end point of
46. Alousi AM, Weisdorf DJ, Logan BR, et al: Etanercept, mycophenolate, graft-versus-host disease-free, relapse-free survival after allogeneic hema-
denileukin, or pentostatin plus corticosteroids for acute graft-versus-host topoietic cell transplantation. Blood 125(8):1333–1338, 2015.